Purpose: Most definitions of visual impairment focus on the status of the better-seeing eye only, but this approach might underestimate the influence of the worse-seeing eye on the vision-related quality of life (VRQoL).
Background
The assessment of visual impairment poses the analytical challenge that both eyes could be affected differently. Most common definitions of visual impairment meet this challenge by focusing on the visual function of the better-seeing eye only -e.g., the definition of blindness of the World Health Organization and Global Burden of Disease Study [1, 2] . However, there is increasing evidence that this approach underestimates the influence of the worse-seeing fellow eye on visual function and vision-related quality of life (VRQoL) [3, 4] . The Melbourne Visual Impairment Project showed that even unilateral vision loss caused difficulties in reading and recognizing faces and increased the risk of falling when away and becoming dependent in persons aged 40 years and older [5] . Additionally, there is evidence from outcome studies that patients who underwent cataract surgery in both eyes reported greater improvement in quality of life than patients who underwent surgery in only one eye [6, 7] . Studies in patients with age-related macular degeneration showed that bilateral manifestation is associated with lower VRQoL than unilateral manifestation [8] . Finger et al. showed that calculating patient reported utilizes based on the better-seeing eye only is likely to underestimate the impact of visual impairment [4] . To further elucidate the contribution of both eyes to VRQoL, we explored in a large populationbased sample whether VRQoL is different when stratifying participants according to the visual acuity of their better-seeing eye only and compared this to also considering the visual acuity of the fellow eye (e.g., the worse-seeing eye). We hypothesize that there will be a substantial impact of the worse-seeing eye on VRQoL.
Materials and methods

Study population
We analyzed a subsample of the Gutenberg Health Study (GHS) with data on both visual acuity and VRQoL available. The GHS is a population-based, single-center, prospective, cohort study at the medical center of the Johannes Gutenberg University Mainz in Germany [9] . The population sample was randomly drawn via local residents' registration offices and equally stratified by sex for each decade of age. The baseline examination included 15,010 participants aged 35 to 74 years and was conducted from 2007 to 2012. The examination consisted of an ophthalmological examination, general and cardiovascular examinations, and questionnaires and interviews. The ophthalmic branch has been described in detail by Höhn et al. [10] . Briefly, we conducted measurements of autorefraction and distance-corrected visual acuity, intraocular pressure, visual field testing, pachy-and keratometry, and posterior segment photography. We used the NEI VFQ-25 to assess VRQoL. We included all participants who completed this questionnaire and with available information on the visual acuity of both eyes.
VRQoL data acquisition and analysis
Vision-related QoL was assessed using the German version of the NEI VFQ-25 [11, 12] . The German NEI VFQ-25 has been assessed for its psychometric properties and was used by various studies [12] [13] [14] [15] [16] [17] . The questionnaire was self-administered as a print-out at the study site and completed using both eyes and reading glasses, if necessary. We used the most common VRQoL instrument and applied state-of-the-art techniques remediating the known flaws-i.e., the violation of unidimensionality and lack of interval-scaled measurementsto analyze the NEI VFQ-25 data. We followed the suggestions of Pesudovs to calculate the "visual functioning scale (VFS)" and "socioemotional scale" (SES); both are interval scaled (0 = worst to 100 = best) and based on the Rasch-transformed individual-level NEI VFQ-25 data [18, 19] . The developers of the questionnaire initially proposed to calculate 12 subscores and one composite VRQoL score (http://www.rand.org/health/surveys_tools/ vfq.html, last accessed 2018-03-27) [18] . Subsequent studies showed that this approach violates unidimensionality and interval-level measurement, both important properties of an instrument measuring QoL [20] [21] [22] [23] [24] . Therefore, we chose the Rasch-based approach described above, as previously used by us and others [18, 19, 25, 26] .
Ocular measurements
Objective refraction and distance-corrected visual acuity were measured in both eyes using a Humphrey Automated Refractor/Keratometer (HARK) 599 (Carl Zeiss AG, Jena, Germany) without cycloplegia, starting with the right eye [10] . Distance-corrected visual acuity was measured using the built-in Snellen charts, ranging from 20/400 to 40/20 (logMAR 1.3 to − 0.3). Below that visual acuity, we used a visual acuity chart at a distance of one meter up to 20/800 (logMAR 1.6), followed by counting fingers, hand movements, and the light perception test. The spherical equivalent was calculated as the spherical correction value plus half of the cylindrical power. A history of eye disease was assessed in a short interview preceding the eye examination.
Sociodemographic characteristics
The socioeconomic status was based on income, education and occupation and was defined according to the German Health Update 2009 (GEDA), with a range from 3 (lowest) to 21 (highest) socioeconomic status [27] .
Statistical analysis
For descriptive analyses, we calculated the mean of the spherical equivalent of both eyes for every participant. Visual acuity measurements were converted to logMAR [28] . We categorized the visual acuity of the better-seeing eye and worse-seeing eye as follows, with the thresholds based on the WHO definition of visual impairment (VI): (0) no VI (< 0.32 logMAR)), (1) mild VI (0.32-0.5 log-MAR), and (2) moderate to severe VI (> 0.5 logMAR) [1, 4] . The subjects were then categorized in 6 groups according to the VI categories of both eyes (Table 1) .
We calculated the median and interquartile range for both VFS and SES for each group. We used linear regression models to estimate the influence of the combination of BE/WE on the VRQoL scores (reference group: no visual impairment in both eyes). We adjusted for age and sex in the basic model and additionally for socioeconomic status in a second model. Additionally, we calculated separate models for participants aged younger than 65 years and those aged 65 years and older. We repeated the analyses restricted to participants without self-reported amblyopia. Amblyopia is characterized by reduced vision since childhood and might have a different impact on VRQoL than visual impairment acquired in later life as affected persons are used to having "one lazy eye" (i.e., only one functioning eye) [29] . The VRQoL might additionally be affected by other nonocular chronic diseases. Therefore, we also calculated models restricted to participants without the following chronic diseases: diabetes mellitus, cardiovascular disease, peripheral artery disease, chronic kidney disease, chronic liver disease, chronic obstructive pulmonary disease, depression, and cancer. Due to the exploratory character of this analysis, p-values were not adjusted for multiple testing. The data were analyzed using GNU R version 3.3.1 [30] .
Results
Our sample consisted of 11,941 GHS participants (49.9% female; median age: 54.7 years) who completed the questionnaire without missing items necessary to calculate the VRQoL scales and with visual acuity of both eyes available. Categorized by the better-seeing eye, n = 11,846 (99.2%) had no VI, n = 69 (0.6%) had mild VI, and n = 26 (0.2%) had moderate to severe VI. The median VRQoL score of the visual functioning scale (VFS) was 89.6 and that of the socioemotional scale (SES) was 100.0. Details of the study sample are shown in Table 2 . Characteristics stratified by sex are shown in the (Additional file 1: Table S1 ).
Categorized only by the better eye, the median scores for the VFS were 89.6 (no VI), 70.2 (mild VI), and 63.2 (moderate to severe VI) ( Table 3) . If the VI of the worse-seeing eye was considered additionally, there was a decrease of approximately four points per VI category in the strata defined by the better-seeing eye (Tables 4 and 5 , Fig 1) . Participants with no visual impairment in the better-seeing eye and mild visual impairment in the fellow eye had a 5.0-point lower VFS score than participants with no visual impairment in both eyes (95% confidence interval (CI) -6.0; − 4.1). Participants with no visual impairment in the better-seeing eye and severe visual impairment in the fellow eye had a 9.0-point lower VFS score than participants with no visual impairment in both eyes (95% CI: − 10.0; − 8.0). These estimates are from the regression model adjusted for age, sex and socioeconomic status (Table 6 ). Different adjustment sets or restrictions to a subsample without general comorbidities or amblyopia resulted in only minor changes in the estimates (Additional files 2, 3, 4, 5, 6 and 7). For all regression coefficients in the main analyses, p was below 0.0001.
The median scores for the SES were 100 (no VI), 88.4 (mild VI), and 76.3 (moderate to severe VI) ( Table 3) . If the worse-seeing eye was considered additionally, there was a decrease of approximately three points per VI category in the stratum of no VI in the better-seeing eye (Tables 6 and 7, Fig. 2 ). In the stratum of the better-seeing eye with mild VI, there was a decrease of 16 points. No VI "b0/w0", n = 11,021
"b0/w1", n = 430 "b0/w2", n = 395
Mild VI / "b1/w1", n = 35
Moderate/ severe VI / / "b2/w2", n = 26
BE Better-seeing eye, WE Worse-seeing eye, VI Vision impairment; no VI: < 0.32 logMAR, mild VI: 0.32-0.5 logMAR; moderate/severe VI: > 0.5 logMAR Continuous variables were described by mean values and standard deviation, and a skewed distribution was described by the median and interquartile range. Discrete variables were described by relative and absolute frequencies. Participants with no visual impairment in the better-seeing eye and mild visual impairment in the fellow eye had a 1.9-point lower SES score than participants with no visual impairment in both eyes. Participants with no visual impairment in the better-seeing eye and severe visual impairment in the fellow eye had a 5.7-point lower SES score than participants with no visual impairment in both eyes (95% CI -6.4; − 5.0). These estimates were from the regression model adjusted for age, sex and socioeconomic status ( Table 7) . The regression results also showed a substantial contribution of both eyes on SES. Adjustment for different potential confounders and excluding general comorbidities did not substantially change the regression estimates. In the subsample without amblyopia, the influence of a worse-seeing eye with moderate/severe VI in addition to a better-seeing eye with no VI was larger than that in the whole sample, and the effect size was similar to mild VI in both eyes (Additional files 2, 3, 4, 5, 6 and 7). For all regression coefficients in the main analyses, p was below 0.0001. In addition to adjusting for age, we calculated separate regression models for participants aged younger than 65 years and those aged 65 years and older. In the younger group, the impact of VI on VFS scores was higher; in both age groups, there was a substantial difference in VFS scores between categories defined by VI of both eyes. For the SES score, the decrease in the groups including the better-seeing eye without visual impairment was larger in the older participants. In the other VI groups, the reduction was more substantial in the younger age group (Additional files 2, 3, 4, 5, 6 and 7).
Discussion
This study showed that the visual acuity of the worse-seeing eye has an important impact on VRQoL in addition to the impact of the better-seeing eye. In a large population-based setting, we showed the additional influence of the worse-seeing eye on VRQoL measured by the most commonly used VRQoL instrument, the NEI VFQ-25. The "one-eye approach", although common, is very likely to neglect the patient's perspective. Our results are in line with previous studies. Finger et al. used the same VI categories to evaluate the impact of the visual impairment of both eyes on patient-reported preferences but did use two other instruments instead of the NEI VFQ-25. There was no effect captured by generic EQ-5D, but the worse-seeing eye had an additional impact on the Vision and Quality of Life Index [4] . Varma et al. showed, in 5270 participants of the Los Angeles Latino Eye Study, that the impacts of unilateral moderate/severe VI and bilateral mild VI on VRQoL were similar, considering that only VI of one eye would have underestimated the real impact [31] . Hirneiss et al. reviewed the influence of both eyes on VRQoL in the context of treatment decisions based on 47 publications [3] . Despite the heterogeneity in study designs and methods applied to assess VRQoL, the authors conclude that treatment of both the better-seeing and worse-seeing eye leads to a benefit in the patients' quality of life, contrary to the common assumption that the better-seeing eye mostly determines VRQoL [3] . There is evidence that, in age-related macular degeneration (AMD), VRQoL is lower in subjects with both eyes affected than in unilateral affected subjects. Dong et al. estimated a difference of six points between both groups when analyzing the NEI VFQ-25 scores [8] . Treatment of AMD leads to an improvement of VRQoL, as shown with the NEI VFQ-25 questionnaire, regardless of whether the better-seeing or worse-seeing eye was treated [32] [33] [34] . For cataract surgery, multiple studies reported an increase of VRQoL in subjects after cataract surgery of the second eye [6, 35, 36] . Schuster et al. used Rasch-transformed NEI VFQ-25 data from the GHS and reported that VRQoL has a similar magnitude in bilateral phakic and pseudophakic subjects, but monolateral pseudophakic subjects have a 6-point lower VRQoL [37] . These results underline the importance of considering both eyes when assessing the impact of VI on patient-reported outcomes. There is no minimal clinically important difference (MCID) for Rasch-transformed NEI VFQ-25 scores; however, because the scale range is similar to the traditional scale ranges (both 0-100 points), the MCID magnitude is expected to be similar. The MCID for traditional NEI VFQ-25 scores is estimated to be four to six points [38, 39] .
The strengths of our study are the large sample size combined with the population-based sampling. The broad assessment of phenotype information is based on a standardized study design and quality controls. Despite the population-based sampling, individuals with bilateral visual impairment are likely to be underrepresented in the GHS cohort because of their lower likelihood to participate. Furthermore, we had a considerable share of participants who did not complete the NEI VFQ-25. At the beginning of the GHS, participants were asked to complete the questionnaire at home. This was then changed to an on-site procedure that greatly increased the rate of participation. Participants with missing NEI VFQ-25 had a reduced physical health, but this seems to be mostly related to general health and less to self-reported eye diseases and ocular parameters [19] . Therefore, we assume the bias due to missing information on VRQoL to be small. Additionally, the numbers in the groups with advanced stages or VI are low, and most participants had no VI. This was to be expected, given the low prevalence of VI in European populations below the age of 75 years and in our population-based study sample [40] . This leads to a reduced precision of the estimates in the groups with advanced stages of VI. Nevertheless, we could show an additional impact on VRQoL of the worse-seeing eye compared with considering the better-seeing eye only. Because the GHS includes a recall every 5 years, we are planning to rerun the analyses in a 10-year older population in the future, where we expect a higher prevalence in VI and to see even more distinct results.
Conclusion
In summary, we demonstrate in a large populationbased study that the visual acuity of the worse-seeing eye has an important impact on VRQoL, in addition to the impact of the better-seeing eye. Whenever possible, the function of both eyes should be considered in medical decision making, as well as in clinical, health care and public health research. 
Availability of data and materials
The analysis presents clinical data of a large-scale population-based cohort with ongoing follow-up examinations. This project constitutes a major scientific effort with high methodological standards and detailed guidelines for analysis and publication to ensure scientific analyses on the highest level. Therefore, the data are not made available for the scientific community outside the established and controlled workflows and algorithms. To meet the general idea of the verification and reproducibility of scientific findings, we offer access to data at the local database in accordance with the ethics vote upon request at any time. The GHS steering committee, which comprises a member of each involved department and the coordinating principal investigator of the Gutenberg Health Study (PSW), convenes once a month. The steering committee decides on internal and external access of researchers and the use of the data and biomaterials based on a research proposal to be supplied by the researcher. Interested researchers make their requests to the coordinating principal investigator of the Gutenberg Health Study (Philipp S. Wild; philipp.wild@unimedizin-mainz.de). More detailed contact information is available at the homepages of the GHS (www.gutenberghealthstudy.org) or ophthalmic branch of the GHS (www.unimedizin-mainz.de/augenklinik/ forschung/gutenberg-gesundheitsstudie.html).
